Sign In

Paul Kelly

Dr. Paul Kelly is a Founding Partner at OneVentures and serves as a Non-Executive Director at BiVACOR Inc. He is an Australian physician with a distinguished career in biotechnology entrepreneurship and healthcare investing.12

Background and Education

Dr. Kelly holds the following qualifications:

  • MBBS(Hons)
  • MD
  • FRACP (Fellow of the Royal Australasian College of Physicians)12

Professional Experience

Dr. Kelly has over 30 years of experience in developing and commercializing biomedical innovations across the United States, Europe, United Kingdom, and Australia.2 His notable achievements include:

  • Co-founder and CEO of Gemini Genomics (Nasdaq)
  • Co-founder of Agamatrix, a leading bio-sensing medical device company
  • Co-founder of Atomera (Nasdaq: ATMR)
  • President and CEO of Orchid Cellmark (Nasdaq)
  • President and CEO of Medcenter Solutions

Current Roles

  • Founding Partner at OneVentures
  • Non-Executive Director at BiVACOR Inc
  • Non-Executive Director at Clinical Genomics
  • Non-Executive Director at Garvan Institute of Medical Research
  • Chair of OneVentures investee companies Vaxxas and Hatchtech
  • Non-Executive Director at Prota Therapeutics123

Dr. Kelly leads the healthcare and biotechnology practice at OneVentures and serves on the investment committees of the firm's main funds.2

Research and Publications

Before his career in biotechnology, Dr. Kelly was a researcher and physician specializing in endocrinology at St Vincent's Hospital, Sydney. He has authored over 100 scientific publications in genetic epidemiology of common metabolic disorders, appearing in prestigious journals such as Nature, New England Journal of Medicine, and The Lancet.2

Dr. Paul Kelly's extensive experience in healthcare, biotechnology, and investment makes him a valuable asset to BiVACOR Inc and other organizations he serves.

Highlights

Dec 12 · DealStreetAsia
Asia Digest: PE firm Hillhouse acquires Australia's George Clinical ... - DealStreetAsia
Asia Digest: PE firm Hillhouse acquires Australia's George Clinical ... - DealStreetAsia
Profile: Dr Paul Kelly - OneVentures
May 20 · biospace.com
BiVACOR® Closes $19 Million Series B and Awarded ... - BioSpace

Related Questions

What are Paul Kelly's key achievements at BiVACOR Inc?
How did Paul Kelly's career evolve from medicine to biotechnology?
What other companies does Paul Kelly currently serve on the board of?
What is the significance of the FDA approval for BiVACOR's Total Artificial Heart?
How has Paul Kelly's work impacted healthcare innovation globally?
Paul Kelly
Paul Kelly, photo 1
Paul Kelly, photo 2
Add to my network

Location

Sydney, Australia